One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Penumbra logo
Penumbra PEN
$ 324.88 0.08%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Penumbra Cash Flow 2025-2011 | PEN

Brief overview of Penumbra's cash movements

Cash flow changes are traced through the five latest available reports from 2021 to 2025.

Operating cash flow reached $238.7 million versus $9.5 million initially. Growth of +2,411.7% at roughly 123.9% CAGR was robust.

Positive cash generation persisted in 4 of five years, so stability is not unconditional.

Across five periods, operating cash flow equaled about 1.6x of cumulative net income. Earnings were strongly backed by cash.

Operating cash flow margin improved from 1.3% to 17%. The quality of revenue growth strengthened.

An additional $202.8 million became tied up in estimated working capital, equal to 14.4% of revenue.

Conclusion

Penumbra's profile is more positive than negative: operations generate cash, although the free cash cushion is not unlimited.

Annual Cash Flow Penumbra

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

239 M 168 M 97.3 M -55.7 M 9.5 M -33.2 M 26.7 M 28.8 M 12.7 M -12.8 M -20.7 M -6.39 M -3.4 M - -

Depreciation & Amortization

17.5 M 23.7 M 27.3 M 24.3 M 16.4 M 12.9 M 8.1 M 6.17 M 3.78 M 2.3 M 1.75 M 751 K 677 K - -

Accounts Payables

34.7 M 31.3 M 27.2 M 26.7 M 13.4 M 14.1 M 15.1 M 8.18 M 6.76 M 4.11 M 2.57 M - - - -

Accounts Receivables

190 M 168 M 202 M 203 M 134 M 115 M 106 M 81.9 M 58 M 43.3 M 29.4 M - - - -

Total Inventories

432 M 407 M 388 M 334 M 264 M 220 M 153 M 116 M 94.9 M 73 M 56.8 M - - - -

All numbers in USD currency

Quarterly Cash Flow Penumbra

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

133 M 87 M - - 49 M - - 38.3 M - - 13.1 M - -57 M - -4.51 M - 18.8 M - -14.4 M - -31.2 M -27.6 M -5.92 M - 21.9 M -165 K -2.07 M - 21.3 M 10.8 M 10.7 M - 13.6 M 2.84 M 2.19 M - -2.45 M -8.18 M -2.07 M - -12.6 M -8.33 M -2.66 M - -993 K - - - - - - - - - - - - - -

Depreciation & Amortization

10.2 M 4.57 M 182 K 178 K 5.02 M 176 K 2.55 M 7.52 M 2.55 M 2.55 M 6.58 M - 2.55 M 2.04 M 5.73 M - 10.7 M 278 K 3.47 M - 9.43 M 6.09 M 2.96 M - 5.79 M 3.74 M 1.8 M - 4.46 M 2.95 M 1.4 M - 2.58 M 1.42 M 654 K - 700 K 600 K 538 K - 500 K 400 K 338 K - 200 K - - - - - - - - - - - - - -

Accounts Payables

44.7 M 43.7 M 29.8 M 28.1 M 31.2 M 33.2 M 32.8 M 32.5 M 28 M 25.8 M 28.2 M 26.7 M 25.4 M - 14.1 M 13.4 M 13.7 M - 15.4 M 14.1 M 14.1 M 14.1 M 14.1 M 15.1 M 15.1 M 15.1 M 15.1 M 8.18 M 8.18 M 8.18 M 8.18 M 6.76 M 6.76 M 6.76 M 6.76 M 4.11 M 4.11 M 4.11 M 4.11 M 2.57 M 2.57 M 2.57 M 2.57 M 2.35 M 2.35 M - - - - - - - - - - - - - -

Accounts Receivables

190 M 183 M 183 M 176 M 168 M 176 M 201 M 192 M 207 M 209 M 207 M 203 M 189 M - 143 M 134 M 120 M - 126 M 115 M 115 M 115 M 115 M 106 M 106 M 106 M 106 M 81.9 M 80.4 M 74.1 M 65.1 M 58 M 58 M 58 M 58 M 43.3 M 43.3 M 43.3 M 43.3 M 29.4 M 29.4 M 29.4 M 29.4 M 18.9 M 18.9 M - - - - - - - - - - - - - -

Total Inventories

443 M 439 M 432 M 428 M 416 M 393 M 374 M 398 M 374 M 359 M 344 M 334 M 320 M - 274 M 264 M 258 M 255 M 245 M 220 M 220 M 220 M 220 M 153 M 153 M 153 M 153 M 116 M 116 M 116 M 116 M 94.9 M 94.9 M 94.9 M 94.9 M 73 M 73 M 73 M 73 M 56.8 M 56.8 M 56.8 M 56.8 M 33.5 M 33.5 M - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Penumbra, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.7 -1.12 % $ 384 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 71.03 0.41 % $ 2.41 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 1.78 % $ 3.4 M usaUSA
AxoGen AxoGen
AXGN
$ 38.31 0.64 % $ 1.76 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 6.78 0.37 % $ 1.68 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 47.96 -2.48 % $ 1.49 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.05 -1.04 % $ 256 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 14.66 1.66 % $ 525 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Globus Medical Globus Medical
GMED
$ 81.12 -0.36 % $ 11 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.07 1.34 % $ 925 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.77 -1.43 % $ 890 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.41 1.69 % $ 99 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.12 -4.69 % $ 14.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.76 -0.12 % $ 1.09 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.54 -0.01 % $ 4.4 B usaUSA
Inogen Inogen
INGN
$ 7.05 -0.77 % $ 188 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.98 0.68 % $ 8.8 B usaUSA